MedTrace Logo

A Double-blind and Randomized Trial of Celecoxib Added to Risperidone in Treatment-naive First-episode Schizophrenia

NCT00686140 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 200

Last updated 2016-07-12

No results posted yet for this study

Summary

A double-blind, randomized, placebo-controlled trial of celecoxib as an add-on therapy to risperidone compared to risperidone plus placebo in the treatment of 200 treatment-naive first-episode patients with schizophrenia. The study addresses an immune dysfunction hypothesis of schizophrenia.

Conditions

Interventions

DRUG

celecoxib

400mg/day, twice a day, 12 weeks

DRUG

Placebo

twice a day, 12 weeks

Sponsors & Collaborators

  • Stanley Medical Research Institute

    collaborator OTHER

  • Beijing HuiLongGuan Hospital

    lead OTHER

Principal Investigators

  • Lian Y Cao, M.D. · Beijing HuiLongGuan Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2006-06-30
Primary Completion
2007-12-31
Completion
2008-03-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00686140 on ClinicalTrials.gov